Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.56 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.52 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836086 | 1.00 | CRBN (0.56) | CRBNOR51E2FKBP5GAAHIF1A | |
| SCHEMBL19302009 | 1.00 | CRBN (0.56) | CRBNOR51E2FKBP5GAAHIF1A | |
| SCHEMBL89391 | 1.00 | — | — | |
| SCHEMBL15043633 | 1.00 | CRBN (0.56) | CRBNOR51E2FKBP5GAAHIF1A | |
| Hydrochloric Acid SCHEMBL2917967 | 0.97 | — | — | |
| SCHEMBL15043647 | 0.92 | OR51E2 (0.52) | CRBNOR51E2FKBP5GAAHIF1A | |
| SCHEMBL15963173 | 0.92 | CRBN (0.48) | CRBNOR51E2FKBP5GAAHIF1A | |
| Acetic Acid SCHEMBL7682459 | 0.86 | CRBN (0.42) | CRBNOR51E2FKBP5GAAGABRP | |
| SCHEMBL29352820 | 0.83 | — | — | |
| SCHEMBL421691 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968176-B2 | Pyrrolidone derivatives, oligomers and polymers | NANOSYNTHONS LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190352258-A1 | PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS | NANOSYNTHONS LLC (US) | 2019-11-21 | — | — | US | disclosed |
| US-10420849-B2 | Pyrrolidone derivatives, oligomers and polymers | NANOSYNTHONS LLC (US) | 2019-09-24 | — | — | US | disclosed |
| US-20170246323-A1 | PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS | NANOSYNTHONS LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246323-A1 | PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS | NANOSYNTHONS LLC (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968176-B2 | Pyrrolidone derivatives, oligomers and polymers | POF1B, VGF, RAB5IF | CRBN 3513/4885OR51E2 2155/4885FKBP5 3235/4885 |
| US-20190352258-A1 | PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS | POF1B, VGF, RAB5IF | CRBN 3513/4885OR51E2 2155/4885FKBP5 3235/4885 |
| US-20170246323-A1 | PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS | POF1B, VGF, RAB5IF | CRBN 3653/4885OR51E2 2308/4885FKBP5 3340/4885 |
| US-10420849-B2 | Pyrrolidone derivatives, oligomers and polymers | POF1B, VGF, RAB5IF | CRBN 3653/4885OR51E2 2308/4885FKBP5 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.